Outcome of Treatment of Chronic Hepatitis C Patients by New Antiviral Drugs

Authors

  • Sharehan Abdelrahman Ibrahim1, Ibrahim Abdelghany Motawea2, Ghada Mohammed Elsagheir3, Ragaa Abdelshaheed4

DOI:

https://doi.org/10.37506/ijphrd.v11i3.1557

Keywords:

Direct-acting antiviral agents (DAAs); Hepatitis C virus; Side effects.

Abstract

HCV constitutes a significant health burden worldwide. Hepatitis C is a disease with significant global
impact. Egypt has a high prevalence of HCV worldwide (>10%) . In Africa and the western Pacific the
prevalence (? 3%) is significantly higher than in North America and Europe (<2%). In general, everyone
with chronic HCV should receive antiviral therapy. This is because patients who are cured of their HCV
infection benefit from reduction in the risk of hepatocellular carcinoma, liver related mortality and even allcause
mortality.In general, everyone with chronic HCV should receive antiviral therapy, treatment should be
given first to patients with advanced fibrosis and high risk for liver-related complications. Also, patients with
severe extrahepatic HCV manifestations should be given high priority. The timing of treatment in patients
with mild liver disease can be individualized. This review provides insight into clinical studies of NS3/4A
protease inhibitors, NS5B viral polymerase inhibitor (nucleotide and non-nucleotide), and NS5A inhibitors,
alone and in combination.

Author Biography

  • Sharehan Abdelrahman Ibrahim1, Ibrahim Abdelghany Motawea2, Ghada Mohammed Elsagheir3, Ragaa Abdelshaheed4

    1Assistant Lecturer of Internal Medicine, Faculty of Medicine, Minia University, Egypt, 2Professor of Internal
    Medicine, Faculty of Medicine, Helwan University, Egypt, 3Professor of Internal Medicine, Faculty of Medicine,
    Minia University, Egypt, 4Assistant Professor of Internal Medicine, Faculty of Medicine, Minia University, Egypt

Downloads

Published

2020-03-26

How to Cite

Outcome of Treatment of Chronic Hepatitis C Patients by New Antiviral Drugs. (2020). Indian Journal of Public Health Research & Development, 11(3), 1129-1133. https://doi.org/10.37506/ijphrd.v11i3.1557